Ranibizumab in Patients With Branch Retinal Vein Occlusion

Study Overview
=================
Brief Summary
-----------------
In a recent study we could show that the early retinal venous vasoconstriction after grid photocoagulation in branch retinal vein occlusion (BRVO) is closely correlated to the visual outcome after three months. This could be of clinical importance, because the degree of vasoconstriction might be an early marker of treatment success, compatible with the idea that hypoxia is the major trigger of VEGF in BRVO. The present study evaluates the response of retinal vessel diameters to anti VEGF treatment with lucentis in patients with BRVO. This is done in an effort to gain insight into the retinal hemodynamic consequences of anti VEGF treatment in BRVO. The hypothesis that anti VEGF treatment is associated with a vasoconstrictor response in retinal vessel in patients with BRVO is tested.

Detailed Description
-----------------
To investigate the response of retinal vessel diameters to lucentis treatment in patients with BRVO and to correlate these changes with changes in functional outcome after 3 months. Pilot study in patients scheduled for intravitreal anti-VEGF (Lucentis™) treatment with BRVO 30 patients with BRVO scheduled for intravitreal anti-VEGF treatment Intravitreous administration of Ranibizumab (Lucentis ™) Main outcome measure: Retinal vessel diameters Secondary outcome measures: Retrobulbar flow velocities, best-corrected visual acuity, macular sensitivity assessed with Microperimetry, objective functional response assessed with mfERG, anatomic changes in the macula region as assessed with StratusOCT and prototype of a Cirrus-OCT(which is available at the Department of Ophthalmology, Medical University of Vienna), angiographical outcomes.

Official Title
-----------------
Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO)

Conditions
-----------------
Retinal Vein Occlusion

Intervention / Treatment
-----------------
* Drug: Lucentis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female, at least 18 years of age. ophthalmoscopic evidence of recent BRVO, that is, a history of 3 months. macular edema secondary to BRVO in the study eye scheduled for intravittreal anti-VEGF as primary treatment. retinal thickness of > 300 µm by OCT in the central subfield of the study eye at baseline. VA decrease attributable to the edema. written informed consent has been obtained. female patients of childbearing potential must have a negative urine pregnancy test. Exclusion Criteria: Uncontrolled sytemic disease Symptoms of a clinically relevant illness in the 3 weeks before the first study day Any ocular condition that in the opinion of the investigator would prevent a 15-letter improvement in visual acuity (eg severe macular ischemia) History of glaucoma, aphakie or presence of anterior chamber intraocular lens, active reinal neovascularisation, choroidal neovascularisation, significant cataract, presence of rubeosis iridis, any ocular infection, history of pars plana vitrectomy, anticipated need for ocular surgery in the study eye during the study perios. contraindication to pupil dilation known allergy or contraindication to the use of fluorescein.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lucentis|intravitreally administration of 0.05 ml Lucentis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Main outcome measure: Retinal vessel diameters |  | weeks 1, 4 and 16 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary outcome measures: Retrobulbar flow velocities, best-corrected visual acuity, macular sensitivity, objective functional response, anatomic changes in the macula region, angiographical outcomes. |  | weeks 1,4 and16 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lucentis, macular edema, branch retinal vein occlusion